Blood tests make clinical trials easier by enabling researchers to identify and recruit the right participants from the start, dramatically reducing the time and resources wasted on enrollment failures. When trial organizers can screen potential participants using blood biomarkers—like phosphorylated tau for Alzheimer’s disease or amyloid levels for cognitive decline—they’re able to enroll people who actually have the disease being studied, rather than spending months trying to confirm diagnosis through visits and evaluations. In a landmark study on Alzheimer’s disease called PROGRESS-AD, using amyloid positivity blood screening reduced enrollment screen-failure rates to just 9.9%, compared to the traditional 30%+ dropout rates seen in standard trials.
This shift from hoping the right people show up to actively identifying them through blood science has fundamentally changed how dementia trials operate. Beyond enrollment, blood tests make trials easier by removing geographic and physical barriers that have historically kept people out of research. A patient with advanced dementia who can’t drive three hours to a medical center can now have blood drawn at home or through a mobile phlebotomist, then continue participating in the trial remotely. This accessibility translates directly to higher completion rates, better data quality, and—perhaps most importantly—the ability to include participants who might otherwise be left out of medical progress.
Table of Contents
- How Blood Biomarkers Transform Patient Stratification
- The FDA Data: Why Biomarkers Nearly Quintuple Approval Odds
- Predicting Alzheimer’s Years Before Symptoms Appear
- From Lab to Home: How Remote Blood Collection Reshapes Trial Access
- Screen Failures: The Hidden Cost of Imprecise Eligibility
- At-Home Testing Technology That Meets FDA Standards
- Phosphorylated Tau: The Disease-Specific Marker That Enables Early Recruitment
How Blood Biomarkers Transform Patient Stratification
Biomarkers play a central role in stratifying trial participants by ensuring everyone enrolled has similar disease biology and is likely to respond to the treatment being tested. Instead of recruiting anyone with a memory complaint and hoping they have Alzheimer’s disease, researchers can now use a blood test for phosphorylated tau or amyloid-beta to confirm the actual pathology in the brain. This precision targeting creates more efficient trials because participants are matched—their biomarker profiles are similar, their disease mechanisms are aligned, and their response patterns become more predictable. The difference is substantial. When a trial enrolls 100 people based on clinical diagnosis alone, perhaps only 60 actually have the disease state researchers intended to study.
But when those same 100 people are prescreened with blood biomarkers, 95 of them have confirmed disease pathology. That’s 35 fewer wasted participant slots, 35 fewer unsuccessful treatment courses clouding the data, and 35 fewer dropouts who felt like the trial wasn’t working for them. Research from the FNIH Biomarkers Consortium confirms that biomarkers are among the most effective tools for identifying patient categories most likely to respond to particular medications. One limitation worth noting: biomarker thresholds themselves become a source of screen failures. If a trial requires a p-tau217 level above 55 pg/mL and someone tests at 52 pg/mL, they’re out, even if clinically they appear to be in the early stages of disease. Strict biomarker cutoffs can help ensure a more uniform study population, but they also exclude people who might have benefited from the treatment.
The FDA Data: Why Biomarkers Nearly Quintuple Approval Odds
When pharmaceutical companies incorporate blood biomarkers into their trial designs, the likelihood that the resulting drug will eventually gain FDA approval rises dramatically—nearly fivefold across all disease indications combined, according to analysis of biomarker-driven oncology and neurology trials published in the NCBI database. This isn’t coincidence. A trial designed around biomarker selection produces cleaner results, faster enrollment, fewer unexpected dropouts, and ultimately clearer proof that the drug actually works in the population it’s meant to help. Why does this approval boost matter for dementia research? Because it means pharmaceutical companies are increasingly willing to invest in dementia trials that use blood biomarkers.
A trial that has an 80% likelihood of showing results that satisfy FDA reviewers attracts more funding, better participants, and more rigorous oversight than a trial expected to fail. This creates a positive feedback loop: better trials attract more investment, which leads to more treatment options for dementia and cognitive decline. The tradeoff is that biomarker-driven trials are more expensive and complex to design upfront. researchers must validate the biomarker, establish cutoff values, train labs to run the test consistently, and often pay for blood draws and analysis for screening participants who won’t be enrolled. That initial investment is substantial, but the payoff—a trial that reaches its goals faster and produces approvable results—more than compensates.
Predicting Alzheimer’s Years Before Symptoms Appear
A February 2026 study from the FNIH Biomarkers Consortium demonstrated that blood tests can now predict when an Alzheimer’s disease symptoms will begin with a margin of error of 3 to 4 years. This capability has transformed how researchers think about prevention trials and early intervention. Instead of waiting for someone to develop memory loss and then enrolling them in a treatment trial, researchers can now identify cognitively normal people who will develop symptoms within the next few years and invite them to join studies testing whether a drug can delay or prevent those symptoms. This predictive power changes trial design entirely. A prevention trial that enrolls people predicted to decline in the next 3 years will show results much faster than a trial enrolling people with mild cognitive impairment who may or may not progress.
The company behind the drug gets faster feedback on whether the treatment works. The research community gets answers about prevention strategies years sooner than would have been possible under the old model. And for participants, there’s the possibility of receiving a treatment that might help them avoid or delay the cognitive decline they would otherwise experience. Phosphorylated tau blood tests—particularly the p-tau217 assay—are especially useful for this predictive role because they are highly specific to Alzheimer’s disease and distinguish it from other dementias like vascular dementia or Lewy body disease. A positive p-tau217 result doesn’t just mean someone has cognitive decline; it means they have Alzheimer’s pathology specifically, which makes enrollment in an Alzheimer’s-focused trial appropriate and likely to be successful.
From Lab to Home: How Remote Blood Collection Reshapes Trial Access
One of the most transformative developments in clinical trials has been FDA guidance permitting decentralized trial elements, including remote and in-home blood collection procedures. This legitimacy has led to widespread adoption of remote blood draws in dementia trials, where many participants are elderly, have mobility limitations, or live in rural areas far from research centers. A trial participant with advanced dementia might not be able to spend two hours traveling to a medical center, sitting in a waiting room, and navigating an unfamiliar environment—but they can schedule a home nursing visit. Multiple remote collection methods now exist: professional home nursing visits where a trained phlebotomist comes to the participant’s home, mobile phlebotomists who travel to specified locations, and self-collection devices like the Tasso+ lancet patch, which received FDA 510(k) clearance and achieves a 94.2% success rate in participant self-collection. Each method has tradeoffs. Home nursing visits are most comfortable and most reliable but most expensive.
Self-collection is cheapest and most convenient but requires participant cooperation and comfort with needles. Mobile phlebotomists split the difference, bringing professional collection to the community without the full overhead of home visits. The impact on trial completion is measurable. Standard dropout rates in phase 3 trials often exceed 30%—people withdraw because they can’t manage repeated travel, they’re too fatigued, transportation costs too much, or they’re simply too ill to visit a clinic. Trials offering home blood collection report substantially lower dropout rates, particularly among participants over 75 or those with advanced cognitive decline. For dementia research specifically, this accessibility difference can mean the difference between a trial that completes with 60% of participants finishing versus 85% finishing—a massive improvement in data quality.
Screen Failures: The Hidden Cost of Imprecise Eligibility
While biomarkers reduce screen failures overall, the eligibility thresholds themselves can create new barriers. Biomarker eligibility criteria are among the strongest protocol-level drivers of enrollment performance, and the stricter those criteria, the higher the screen failure rate becomes. In inflammatory bowel disease trials, screen-failure rates averaged 44% in ulcerative colitis and 51% in Crohn’s disease, primarily driven by biomarker and disease activity thresholds that excluded participants who didn’t meet exact specifications. For dementia trials, a similar phenomenon occurs. If a trial requires a Mini-Cog score of 15–22 and amyloid-beta below a certain threshold and phosphorylated tau above another threshold, many people who present with cognitive decline will fail to meet all criteria simultaneously.
Someone might have the right biomarker profile but slightly better cognition than the protocol allows, or someone might have the cognitive decline but not yet show the expected biomarker signature. These mismatches aren’t failures of the blood test—they’re features of how disease develops. Not everyone progresses through the stages of dementia at the same pace or with the same biomarker sequence. The warning here is that overly restrictive biomarker-based eligibility can inadvertently create trials that study only a narrow slice of the disease, then claim the drug works for “Alzheimer’s disease” when really it works for a very specific subtype. Balancing precision in participant selection against the need for a representative, generalizable study population remains an ongoing challenge.
At-Home Testing Technology That Meets FDA Standards
The Tasso+ at-home blood collection device exemplifies how technology has solved the logistical problems that made traditional trial blood draws inconvenient. Participants use a lancet patch to prick their finger, collect several drops of blood on a special collection card, and mail the sample to the testing laboratory. The device achieved FDA 510(k) clearance based on a 94.2% success rate—meaning 94 out of 100 participants successfully collected usable blood samples on their first attempt.
This success rate matters because it means researchers can rely on at-home collection as a core trial component, not a backup option. Participants in early-stage Alzheimer’s trials can now complete quarterly blood draws at home without travel burden, and the labs can depend on receiving analyzable samples. The convenience removes one more barrier to continued participation, especially for aging populations with transportation limitations or caregivers who can’t easily drive them to appointments.
Phosphorylated Tau: The Disease-Specific Marker That Enables Early Recruitment
Phosphorylated tau 217 (p-tau217) blood tests have become the gold standard for identifying Alzheimer’s disease specifically, rather than general cognitive decline from other causes. The test can detect Alzheimer’s pathology years before symptoms appear, and it is highly specific—meaning a positive p-tau217 result is much more likely to indicate Alzheimer’s disease than false positives from vascular disease, depression, or normal aging. This specificity allows trial organizers to confidently recruit participants into Alzheimer’s-focused treatment studies, knowing that enrolled participants actually have the disease mechanism the treatment targets.
In recent Alzheimer’s trials, p-tau217 has been used both for participant screening (confirming someone has Alzheimer’s pathology before enrolling them) and during-trial monitoring (tracking whether the blood biomarker improves alongside cognitive outcomes). This dual use means blood tests serve as a continuous validation that the trial is measuring what it claims to measure. A participant’s p-tau217 level, combined with cognitive testing and imaging, creates a robust picture of disease status and progression, giving researchers confidence that any observed treatment effect is real and not an artifact of disease heterogeneity or placebo response.
- —
